parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in ependymal cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	6 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 6602

receipt 6611: ARNT2 in dopamine neurons, braak

power: full sample -0.17 (p 0.498, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.33 (p 0.185, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to -0.06, sign flips 0; without severely affected donors -0.17 (p 0.498, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARNT2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6610: ARNT2 in oligodendrocytes, braak

power: full sample -0.13 (p 0.615, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.15 (p 0.561, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.18 (p 0.482, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to +0.00, sign flips 1; without severely affected donors -0.13 (p 0.615, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARNT2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts